罗沙司他联合静脉铁剂治疗维持性血液透析患者肾性贫血的效果

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (612 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of Roxadustat combined with intravenous iron in the treatment of renal anemia of maintenance hemodialysis patients.Methods A total of 81 maintenance hemodialysis patients with renal anemia admitted to University Town Hospital Affiliated Chongqing Medical University Dialysis Center from January 2020 to September 2022 were selected as research objects,and they were divided into control group(41 cases)and observation group(40 cases)according to different treatment methods.The control group was treated with recombinant human erythropoietin combined with intravenous iron and the observation group was treated with Roxadustat combined with intravenous iron.The hematocrit(HCT),red blood cell count(RBC),hemoglobin(Hb),total iron binding capacity(TIBC),serum iron(SI),serum ferritin(SF)and C-reactive protein (CRP)were compared between the two groups.Results After treatment,the HCT,RBC,Hb,TIBC,SI and SF of the two groups were higher than those before treatment,the HCT,RBC,Hb,TIBC,SI and SF of the observation group were higher than those of the control group,and the CRP of the observation group was lower than that before treatment and that of the control group,with significant differences(P＜0.05).Conclusion The treatment of Roxadustat combined with intravenous iron can obviously improve the indicators of anemia in patients with uremia,significantly improve the iron metabolism index,and reduce the inflammatory factors.

Key words： Roxadustat Intravenous iron Erythropoietin Renal anemia Maintenance hemodialysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2023/V30/I21/14

[1]	赵璐，刘虹.慢性肾脏病患者的炎症状态及其对肾性贫血治疗的影响[J].中国血液净化，2020，19（3）：149-152.
[2]	Nakhoul G，Simon JF.Anemia of chronic kidney disease：Treat it，but not too aggressively[J].Cleve Clin J Med，2016，83（8）：613-624.
[3]	Hazin MAA.Anemia in chronic kidney disease[J].Rev Assoc Med Bras（1992），2020，66（Suppl 1）：s55-s58.
[4]	Akizawa T，Yamaguchi Y，Majikawa Y，et al.Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients[J].Ther Apher Dial，2021，25（5）：575-585.
[5]	Groenendaal-van de Meent D，Kerbusch V，Kaspera R，et al.Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat，an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor[J].Eur J Drug Metab Pharmacokinet，2021，46（1）：141-153.
[6]	中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识（2018 修订版）[J].中华肾脏病杂志，2018，34（11）：860-866.
[7]	Zhou QG，Jiang JP，Wu SJ，et al.Current pattern of Chinese dialysis units：a cohort study in a representative sample of units[J].Chin Med J（Engl），2012，125（19）：3434-3439.
[8]	李福兴，谢可心，张玉琳，等.铁调素在脓毒症相关性贫血中的研究进展[J].解放军医学杂志，2020，45（12）：1299-1303.
[9]	Abboud S，Haile DJ.A novel mammalian iron-regulated protein involved in intracellular iron metabolism[J].J Biol Chem，2000，275（26）：19906-19012.
[10]	Chung J，Wessling-Resnick M.Molecular mechanisms and regulation of iron transport[J].Crit Rev Clin Lab Sci，2003，40（2）：151-182.
[11]	Conrad ME，Umbreit JN.Iron absorption and transport-an update[J].Am J Hematol，2000，64（4）：287-298.
[12]	Knutson MD，Oukka M，Koss LM，et al.Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin[J].Proc Natl Acad Sci USA，2005，102（5）：1324-1328.
[13]	剌嫣瑾，于为民，任小军.低氧诱导因子治疗肾性贫血的Meta 分析[J].中国中西医结合肾病杂志，2020，21（1）：40-44，95.
[14]	谢院生，李清刚.肾脏病学临床研究新进展[J].中国中西医结合肾病杂志，2020，21（6）：471-473.
[15]	Renassia C，Peyssonnaux C.New insights into the links between hypoxia and iron homeostasis[J].Curr Opin Hematol，2019，26（3）：125-130.
[16]	支爽，李冬冬.HIF 脯氨酰羟化酶抑制剂治疗肾性贫血的临床研究进展[J].中国新药与临床杂志，2018，37（7）：379-384.
[17]	王培培，吴涛.口服罗沙司他对慢性肾脏病并肾性贫血的治疗效果观察[J].山东医药，2020，60（33）：73-75.
[18]	黄世杰.罗沙唐司他明显增加慢性肾病贫血患者的血红蛋白水平[J].国际药学研究杂志，2020，47（8）：618.
[19]	Carrero JJ，Stenvinkel P.Inflammation in end-stage renal disease--what have we learned in 10 years?[J].Semin Dial，2010，23（5）：498-509.
[20]	李海男，印璞，金玉芬，等.慢性肾脏病促红细胞生成素抵抗原因分析及研究进展[J].中国实验诊断学，2020，24（11）：1927-1931.
[21]	朱如月，肖晓晨，王莳萍.超敏C 反应蛋白及血脂指标在脂肪肝中的变化及临床意义[J].检验医学与临床，2019，16（13）：1898-1900.
[22]	Bailie GR，Larkina M，Goodkin DA，et al.Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality[J].Kidney Int，2015，87（1）：162-168.